KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Change in Cash (2019 - 2025)

Historic Change in Cash for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $307.0 million.

  • Royalty Pharma's Change in Cash rose 13769.2% to $307.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.1 million, marking a year-over-year decrease of 18165.25%. This contributed to the annual value of $452.0 million for FY2024, which is 13663.78% up from last year.
  • Per Royalty Pharma's latest filing, its Change in Cash stood at $307.0 million for Q3 2025, which was up 13769.2% from -$455.8 million recorded in Q2 2025.
  • Royalty Pharma's 5-year Change in Cash high stood at $921.6 million for Q2 2024, and its period low was -$1.2 billion during Q3 2023.
  • For the 5-year period, Royalty Pharma's Change in Cash averaged around -$3.7 million, with its median value being $197.4 million (2023).
  • The largest annual percentage gain for Royalty Pharma's Change in Cash in the last 5 years was 37684.13% (2022), contrasted with its biggest fall of 26953.12% (2022).
  • Quarter analysis of 5 years shows Royalty Pharma's Change in Cash stood at -$259.8 million in 2021, then surged by 376.84% to $719.1 million in 2022, then tumbled by 163.89% to -$459.4 million in 2023, then skyrocketed by 95.42% to -$21.0 million in 2024, then skyrocketed by 1560.27% to $307.0 million in 2025.
  • Its Change in Cash stands at $307.0 million for Q3 2025, versus -$455.8 million for Q2 2025 and $158.7 million for Q1 2025.